News & Updates
Filter by Specialty:

Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
08 Jan 2025
Retifanlimab plus chemo improves survival in metastatic NSCLC
The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.
Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
07 Jan 2025
Palbociclib plus ET prolongs survival in metastatic breast cancer
First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.
Palbociclib plus ET prolongs survival in metastatic breast cancer
06 Jan 2025
T-DXd improves PFS in breast cancer with rapid progression
Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.